Tag:
AstraZeneca
Latest Headlines
Latest Headlines
Speculation heats up on fate of AGI-1067
There's an intense amount of market buzz focused on AtheroGenics' lead drug candidate, AGI-1067. The wire services have noted that the company's CEO--Russell M. Medford, M.D., Ph.D (photo)--is preparing to make a presentation at the J.P. Morgan conference next Wednesday and hard data from the Phase III trial is due to be released at the ACC meeting in New Orleans, leading to some speculation that the company is working out the …
Editor's Corner
Here's wishing everyone had a happy holiday break. While we were away for our customary leave, we spotted some notable headlines. Telik scored the biggest news of the past week, reporting that its cancer therapy …
Press Release: Targacept to Receive $20M Milestone Payment as AstraZeneca Plans to Continue Development of AZD3480
Press Release: Targacept to Receive $20M Milestone Payment as AstraZeneca Plans to Continue Development of AZD3480
Glaxo to buy Domantis for $453M
GlaxoSmithKline has announced a deal to buy the UK's Domantis for $454 million--the latest in a string of major buyout deals. In this case, Glaxo is acquiring a leading developer of monoclonal antibodies and has attracted considerable attention to its programs for developing smaller antibodies that can be administered in a variety of ways and reach areas of the body that currently-used antibodies can't. Due to their relatively large molecular size, antibody therapies now have to be …
ALSO NOTED: Alexza gains $50M; AstraZeneca, Cubist sign $10.25M licensing pact; and much more...
> Symphony Capital Partners will provide $50 million to Alexza Pharmaceuticals for the development of AZ-002 and AZ-004, both of which are in Phase II trials. Release > Shanghai-based Cathay Industrial Biotech has closed a $52 million second round of financing. Investors include Goldman Sachs, Gramineae Holdings Company Limited, GM Investment Company Limited and New Horizon Evergreen Investment. …
Dynavax stock jumps on hep B data
Shares of Dynavax Technologies shot up 31 percent in after-hours trading after the developer announced that a late-stage trial of its experimental vaccine for hepatitis B showed that it performed better after two doses than three doses of GlaxoSmithKline's vaccine. Two doses of Hepislav protected 98 percent of volunteers compared to 25 percent protected by two doses of Glaxo's Engerix-B. Analysts say the data shows that Dynavax can successfully compete against Glaxo in the $1 billion …
ALSO NOTED: Bronchitol gains fast track; Alimera garners $15.9M in second tranche; and much more...
> The FDA has granted fast-track status to Pharmaxis' Bronchitol as a therapy for cystic fibrosis. Investors applauded the news by driving up the value of Pharmaxis' stock about 20 percent on Friday. Pharmaxis has released positive mid-stage data on Bronchitol that demonstrates an improvement in lung function among the patients taking the drug. Pharmaxis plans a complete filing for Bronchitol by 2008. …
SPOTLIGHT: AstraZeneca, Par collaborate on authorized generic
AstraZeneca and Par Pharmaceutical have signed an agreement for Par to distribute an authorized generic version of AstraZeneca's Toporol (metoprolol succinate) in the U.S. Authorized generics represent branded pharma's response to the fierce competition they're facing from generic drug companies as a number of blockbuster drugs lose patent protection. Release
Press Release: AstraZeneca, Par Pharmaceuticals collaborate on authorized generic verson of Toprol-XL
Press Release: AstraZeneca, Par Pharmaceuticals collaborate on authorized generic verson of Toprol-XL
Merck KGaA inks deal with China's Chi-Med
Demonstrating the growing importance of China in the drug development field, Merck KGaA has inked a deal that gives the German drug company access to Chi-Med's large Shangha research center as well as its library of botanical compounds. No details were released, but Chi-Med gains an upfront payment and milestones on any new drugs they develop. For Merck, it's a chance to gain a lead in the push to develop new compounds from traditional Chinese medicines. Novartis, Pfizer, …
